Eutilex.Co.,Ltd. discovers and develops immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops anti-tumor T cell therapy and antibody therapeutics. The company was founded in 2015 and is headquartered in Seoul, South Korea.
Stock data | 2024 | Change |
---|---|---|
Price | $2.17 | N/A |
Market Cap | $15.83M | N/A |
Shares Outstanding | 7.29M | N/A |
Employees | 90.00 | N/A |